A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.
A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.
Over 39,000 patients were followed for up to 11 years in a large national study comparing major heart event risks after gastric bypass and sleeve gastrectomy.
Short sleep, late blood draws, and intense workouts significantly change common cardiovascular biomarkers, suggesting key variables often go unaccounted for in heart risk assessments.
A large Canadian study of 3,357 patients found that taking blood pressure medication at bedtime did not reduce deaths or heart events compared to morning dosing.
A large Canadian study of 3,357 patients found that taking blood pressure medication at bedtime did not reduce deaths or heart events compared to morning dosing.